Natera, Aveta Biomics collaborate on head and neck cancer trial

Natera and Aveta Biomics have entered into a strategic partnership to support the latter’s AVTA 30-01, a global Phase III head and neck cancer trial assessing APG-157 in patients with LA-HNSCC. Around 826 participants will be recruited across Australia, Asia-Pacific, Europe and North America. The AVTA 30-01 study builds on Phase II data showing positive safety, tumour control, molecular response and survival. Credit: THICHA SATAPITANON/Shutterstock.com. Natera and Aveta Biomics have entered into a strategic partnership to support the latter’s AVTA 30-01, a global Phase III head and neck cancer trial assessing APG-157 in patients with locally advanced head and neck…

Source: Clinical Trials Arena